DK140837B - Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner. - Google Patents

Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner.

Info

Publication number
DK140837B
DK140837B DK279771AA DK279771A DK140837B DK 140837 B DK140837 B DK 140837B DK 279771A A DK279771A A DK 279771AA DK 279771 A DK279771 A DK 279771A DK 140837 B DK140837 B DK 140837B
Authority
DK
Denmark
Prior art keywords
prostaglandins
cyclodextrins
preparation
analogous process
clathrate compounds
Prior art date
Application number
DK279771AA
Other languages
Danish (da)
English (en)
Other versions
DK140837C (sv
Inventor
Masaki Hayashi
Atsunobu Ishihara
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of DK140837B publication Critical patent/DK140837B/da
Application granted granted Critical
Publication of DK140837C publication Critical patent/DK140837C/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK279771AA 1970-06-10 1971-06-09 Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner. DK140837B (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP45050119A JPS503362B1 (sv) 1970-06-10 1970-06-10

Publications (2)

Publication Number Publication Date
DK140837B true DK140837B (da) 1979-11-26
DK140837C DK140837C (sv) 1981-09-07

Family

ID=12850213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK279771AA DK140837B (da) 1970-06-10 1971-06-09 Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner.

Country Status (22)

Country Link
US (1) US3816393A (sv)
JP (1) JPS503362B1 (sv)
AT (1) AT332570B (sv)
BE (1) BE768288A (sv)
CA (1) CA958007A (sv)
CH (1) CH568259A5 (sv)
CS (1) CS170169B2 (sv)
CY (1) CY895A (sv)
DE (1) DE2128674C2 (sv)
DK (1) DK140837B (sv)
ES (1) ES392074A1 (sv)
FR (1) FR2100745B1 (sv)
GB (1) GB1351238A (sv)
HK (1) HK17577A (sv)
HU (1) HU163135B (sv)
IE (1) IE35326B1 (sv)
NL (1) NL162901C (sv)
NO (1) NO134373C (sv)
RO (1) RO62182A (sv)
SE (1) SE390818B (sv)
SU (1) SU404225A3 (sv)
ZA (1) ZA713398B (sv)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163108A (en) * 1967-02-16 1979-07-31 Lever Brothers Company Prostaglandins
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
US3903131A (en) * 1971-04-12 1975-09-02 Upjohn Co 16 and 16,16-dimethyl PGE{HD 2{B
CA984387A (en) * 1971-04-12 1976-02-24 Barney J. Magerlein Analogs of prostaglandins
US3954833A (en) * 1971-04-12 1976-05-04 The Upjohn Company 16,16-Methyl and ethyl substituted PGF2.sub.α compounds
FR2134673A1 (en) * 1971-04-30 1972-12-08 Ono Pharmaceutical Co Novel optically active isomers of prostaglandin analoguesof natural configuration useful as hypotensive agents, diuretics,contraceptives, for treating gastric ulcer and asthma, and forinhibiting platelet aggregation
US4045467A (en) * 1972-02-18 1977-08-30 May & Baker Limited Cyclopentane derivatives
US4082789A (en) * 1972-03-28 1978-04-04 The University Court Of The University Of Edinburgh Prostaglandins C2
JPS4926258A (sv) * 1972-07-06 1974-03-08
US4110368A (en) * 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4141914A (en) * 1972-07-24 1979-02-27 American Cyanamid Company Novel 11-deoxy-11-substituted prostaglandins of the E and F series
US4130721A (en) * 1972-07-24 1978-12-19 The Upjohn Company 11-Deoxy PGE2 compounds
JPS4942648A (sv) * 1972-08-24 1974-04-22
US3962312A (en) * 1972-09-21 1976-06-08 Ono Pharmaceutical Company 9,11,15-Trihydroxy prost-5-enoic acid analogues
US3972917A (en) * 1972-10-27 1976-08-03 American Home Products Corporation 11-Deoxy 15-methyl prostaglandin E1
JPS5443570B2 (sv) * 1972-10-27 1979-12-20
US4092427A (en) * 1973-04-16 1978-05-30 American Home Products Corporation Method of inducing abortion using alkyl derivatives of prostanoic acids
JPS5623984B2 (sv) * 1973-04-19 1981-06-03
US4246426A (en) * 1973-08-06 1981-01-20 Hoffmann-La Roche Inc. 11-Substituted prostaglandins
US4052446A (en) * 1973-08-06 1977-10-04 Hoffmann-La Roche Inc. 11,16-substituted prostaglandins
US4059576A (en) * 1973-08-06 1977-11-22 Hoffmann-La Roche, Inc. 11-Substituted prostaglandins
US4026927A (en) * 1973-09-25 1977-05-31 Yamanouchi Pharmaceutical Co., Ltd. Novel prostaglandin derivatives
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
GB1448268A (en) * 1973-11-13 1976-09-02 May & Baker Ltd Cyclopentane derivatives
US4041066A (en) * 1974-02-07 1977-08-09 The Upjohn Company 4,5-Cis-didehydro-PGE1 compounds
GB1441564A (en) * 1974-02-07 1976-07-07 Upjohn Co Prostaglandins
DE2416193C2 (de) * 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
US4256651A (en) * 1974-10-02 1981-03-17 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF1β compounds
GB1482010A (en) * 1974-10-28 1977-08-03 Ono Pharmaceutical Co Prostaglandin analogues
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4209637A (en) * 1975-02-24 1980-06-24 The Upjohn Company 2,2-Difluoro-PGF2 analogs
US4207420A (en) * 1975-02-24 1980-06-10 The Upjohn Company 2,2-Difluoro-PGF1 analogs
US4059701A (en) * 1975-04-17 1977-11-22 American Home Products Corporation 15-Substituted prostanoic acids for treating bronchial spasm
FR2313019A2 (fr) * 1975-06-04 1976-12-31 Ono Pharmaceutical Co Nouveaux analogues de prostaglandines et leur procede de preparation
US4086269A (en) * 1975-07-07 1978-04-25 American Home Products Corporation 11-Deoxy-15-substituted prostaglandins
US4026909A (en) * 1975-07-14 1977-05-31 The Upjohn Company Cis-13-PGF2.sub.α analogs
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4016184A (en) * 1975-09-17 1977-04-05 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD1 compounds
US4013695A (en) * 1975-10-02 1977-03-22 The Upjohn Company 4,4,5,5-Tetradehydro-PGE1 analogs
US4053500A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGF1α analogs
US4053502A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGE1 analogs
US4026919A (en) * 1975-10-23 1977-05-31 The Upjohn Company PGD2 Substituted esters
US4058665A (en) * 1975-11-06 1977-11-15 Yamanouchi Pharmaceutical Co., Ltd. Novel 3,15-dilower alkyl PGE2 derivatives
US4212987A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4212986A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE2 analogs
US4169895A (en) * 1976-09-28 1979-10-02 Pfizer Inc. Antisecretory 16,16-dimethyl-17-oxaprostaglandins
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU179141B (sv) * 1977-09-23 1982-08-28
JPS5577440U (sv) * 1978-11-25 1980-05-28
US4244883A (en) * 1979-09-12 1981-01-13 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF2β compounds
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
AU615245B2 (en) * 1987-12-22 1991-09-26 Glaxo Group Limited Aqueous formulations containing a piperidinylcyclopentylheptenoic acid derivative
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DE19828881A1 (de) * 1998-06-22 1999-12-23 Schering Ag Oxidationsinhibitor bei Prostan-Derivaten
US6287603B1 (en) 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
CA2454584C (en) 2001-07-23 2009-09-22 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
WO2005009468A1 (ja) 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
CN100542537C (zh) * 2004-07-27 2009-09-23 中国人民解放军军事医学科学院毒物药物研究所 前列腺素e1口腔制剂
WO2006137958A1 (en) * 2005-06-13 2006-12-28 Cargill Incorporated Cyclodextrin inclusion complexes and methods of preparing same
CN101223183A (zh) * 2005-06-13 2008-07-16 嘉吉公司 环糊精包合复合物及其制备方法
WO2007145663A1 (en) * 2006-06-13 2007-12-21 Cargill, Incorporated Large-particle cyclodextrin inclusion complexes and methods of preparing same
JP2010514794A (ja) * 2006-12-27 2010-05-06 カーギル インコーポレイテッド シクロデキストリン封入複合体および該複合体を調製する方法
KR101492552B1 (ko) 2007-02-16 2015-02-12 오노 야꾸힝 고교 가부시키가이샤 요 배출 장애 치료제
JP5479092B2 (ja) 2007-05-08 2014-04-23 国立大学法人浜松医科大学 Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
EP2441760B1 (en) 2009-06-10 2013-11-20 ONO Pharmaceutical Co., Ltd. Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
JP4890657B1 (ja) * 2011-06-03 2012-03-07 小野薬品工業株式会社 リマプロストとβ−シクロデキストリンを含有する錠剤
RU2627842C2 (ru) 2011-08-02 2017-08-14 Оно Фармасьютикал Ко., Лтд. Средство для улучшения диастолической функции левого желудочка
EP2891651B1 (en) 2012-08-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Amine salt and crystals thereof
PL3456710T3 (pl) 2016-05-09 2021-12-20 AGC Inc. Nowa pochodna prostaglandyny
WO2023037934A1 (ja) * 2021-09-13 2023-03-16 富士フイルム株式会社 ビシクロアルカン化合物の包摂体の製造方法

Also Published As

Publication number Publication date
US3816393A (en) 1974-06-11
NL162901B (nl) 1980-02-15
FR2100745B1 (sv) 1974-08-30
SU404225A3 (sv) 1973-10-26
DK140837C (sv) 1981-09-07
FR2100745A1 (sv) 1972-03-24
CS170169B2 (sv) 1976-08-27
NO134373B (sv) 1976-06-21
CH568259A5 (sv) 1975-10-31
DE2128674A1 (de) 1971-12-16
IE35326B1 (en) 1976-01-07
HU163135B (sv) 1973-06-28
GB1351238A (en) 1974-04-24
NL162901C (nl) 1980-07-15
CA958007A (en) 1974-11-19
NL7107894A (sv) 1971-12-14
ATA480371A (de) 1976-01-15
RO62182A (sv) 1977-07-15
JPS503362B1 (sv) 1975-02-04
NO134373C (sv) 1976-09-29
CY895A (en) 1977-10-07
IE35326L (en) 1971-12-10
HK17577A (en) 1977-04-22
BE768288A (fr) 1971-11-03
ZA713398B (en) 1972-01-26
AT332570B (de) 1976-10-11
DE2128674C2 (de) 1982-06-24
ES392074A1 (es) 1974-08-01
SE390818B (sv) 1977-01-24

Similar Documents

Publication Publication Date Title
DK140837B (da) Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner.
CH524972A (fr) Chaussures, notamment pour enfants
DK128733B (da) Fremgangsmåde til fremstilling af prostaglandinestere.
DK132174B (da) Analogifremgangsmåde til fremstilling af 2,4-diamino-5-benzylpyrimider.
DK129339B (da) Analogifremgangsmåde til fremstilling af N-aminophenylamidiner.
DK127640B (da) Fremgangsmåde til fremstilling af 3,20-dioxo-17α-21-dimethyl-19-norpregna-4,9-dien.
DK135455B (da) Fremgangsmåde til fremstilling af 7-halogen-7-desoxythiolincosaminider.
DK130467B (da) Fremgangsmåde til fremstilling af erythromycylaminer.
DK136975B (da) Analogifremgangsmåde til fremstilling af phenazinderivater.
DK126998B (da) Analogifremgangsmåde til fremstilling af amino-s-triazolylbenzensulfonamidforbindelser.
DK127977B (da) Fremgangsmåde til fremstilling af 6α-methyl-19-nor-pregnener.
DK127812B (da) Analogifremgangsmåde til fremstilling af 3,5-dibrom-zearalan.
DK129453B (da) Analogifremgangsmåde til fremstilling af 1-aminoisoquinoliner.
DK137181B (da) Analogifremgangsmåde til fremstilling af 3-amino-kinolinderivater.
DK128205B (da) Fremgangsmåde til fremstilling af 1-aryloxy-2-propanoler.
DK126323B (da) Fremgangsmåde til fremstilling af 3β-hydroxy-5α-cardenolider eller -bufadienolider.
DK127001B (da) Fremgangsmåde til fremstilling af alkylsilaner.
DK137860B (da) Analogifremgangsmåde til fremstilling af triazolobenzodiazepin-5N-oxydderivater.
DK125388B (da) Fremgangsmåde til fremstilling af phenylaminoethanolderivater.
DK127852B (da) Analogifremgangsmåde til fremstilling af 22-substituerede cardenolidrhamnosider.
DK127414B (da) Analogifremgangsmåde til fremstilling af phenylhydrazider.
DK129049B (da) Analogifremgangsmåde til fremstilling af α-aminobenzylpenicillinderivater.
DK128209B (da) Analogifremgangsmåde til fremstilling af 19-nor-14-dehydrotestosteronderivater.
DK129138B (da) Fremgangsmåde til fremstilling af tuberactinomycin-N.
DK126186B (da) Fremgangsmåde til fremstilling af 13β-alkylgona-4,9-diener.

Legal Events

Date Code Title Description
PBP Patent lapsed